top of page

Next-generation corneal regenerative cell therapy

Advancing epithelial cell-sheet science for corneal repair

Incubation.png

21-day only for tissue cultivation.

IND PHASE 1.png

TFDA IND approved.

Phase 1 Taiwan.

Enrolling patients.

Patent.png

Global patents supporting the platform.

Taipei Medical University.png

Licensed from Taipei Medical University.

Cell-sheet engineering, simply applied.

Our proprietary technology involves culturing a cohesive eye epithelial layer from a patient’s own mucosal cells.

We then re-plant that layer on the eye to help the patients improve the overall eye sight and the quality of lifes.

Copy of Copy of 細胞層片脫著.jpg

Science & Platform

Corneal copy.png

Advancing epithelial cell-sheet science for corneal repair

When the cornea loses its protective surface, vision and comfort suffer.

Our platform cultures a thin, living epithelial sheet from a small sample of a patient’s own cells.

The sheet is then transferred onto the eye to support eye epithelium restoration.

1

Collect Autologous Mucosal Cells

A clinician collects a small sample of mucosal cell from the inner layer of the mouth

Medical Sample Collection Procedure copy.png

2

Culture the Epithelial Sheet

In our lab, the cells are expanded into a cohesive epithelial sheet, typically less than 21 days.

cell collection.png

3

Prepare for Re-Placement

The sheet is inspected, shaped, and replanted back to the cornea of the patients under controlled conditions by a licensed surgeon.

Ophthalmic Surgery Detail_ Eye Implant copy.png

4

Place & Monitor

A physician places the sheet on the eye in a ~30-minute procedure, with follow-ups at 3, 6, and 9 months to assess safety and healing progress.

Eye Examination Focused Precision copy.png

Our impact is practical:

Helping vision impaired patients improve the quality of remaining life one step at a time. 

We created Visionary BioMed to fulfill the unmet medical needs in corneal damaged patients worldwide via advanced cell therapy. Rather than designing around the eye, we engineer a living epithelial sheet that can be placed on the cornea to support recovery.

王進富 David (Chin- Fu) Wang

Chairman & Co-founder

Wang sr - horiz2.png

Visionary Biomed in Numbers

21

Lab cultivation (typical)

~21 days to grow an epithelial sheet; timing varies by protocol.

2025

IND Phase 1 (Taiwan)

Authorization obtained in Nov 2024 for VB-008 first-in-human.

30

Procedure minutes (approx.)

Surgical placement is a short procedure; details depend on site/protocol.

2

Indications in scope

LSCD (lead) and severe Dry Eye (exploratory).

Issued IP in US, Taiwan, and China supporting core methods.

1

Lead program

VB-008—autologous epithelial cell-sheet candidate entering Phase 1.

News

Join Our Team

We are advancing patient-derived epithelial cell-sheet therapy with discipline, clarity, and clinical focus.

R&D Scientist — Epithelial Cell Biology

Taipei, TW

bottom of page